 | • レポートコード：MRC2012B0522 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、122ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、IBS-C薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。IBS-C薬の種類別市場規模（リナクロチド、ルビプロストン、浸透圧性下剤、覚醒剤下剤、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Catalent Pharmaceuticals Solutions、Ardelyx, Inc、Synergy Pharmaceuticals、Nestle、Astellas Pharmaceuticals、Abbott Laboratories、Teva Pharmaceutical Industries、Novartis Pharma Ag、Sucampo Pharmaceuticals、Synthetic Biologics, Inc、Norgine B.V、Albireo Pharma Inc、Bama-Geve, SLU、Astrazeneca Plc、Prometheus Laboratories Inc、Salix Pharmaceuticals Ltd、Ferring BV、Yuhan Corp、Actavis Nordic A/S、Ironwood Pharmaceuticals, Inc、The Menarini Group、Ono Pharmaceutical Co., Ltd、 ・地域別グローバル市場分析 2015年-2020年 ・IBS-C薬の北米市場（アメリカ、カナダ、メキシコ） ・IBS-C薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・IBS-C薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・IBS-C薬の南米市場（ブラジル、アルゼンチン） ・IBS-C薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：リナクロチド、ルビプロストン、浸透圧性下剤、覚醒剤下剤、その他 ・用途別分析：病院薬局、小売薬局、オンライン薬局 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global IBS-C Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The IBS-C Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
IBS-C Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, IBS-C Drugs market has been segmented into:
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
By Application, IBS-C Drugs has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global IBS-C Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level IBS-C Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global IBS-C Drugs market.
The report offers in-depth assessment of the growth and other aspects of the IBS-C Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and IBS-C Drugs Market Share Analysis
IBS-C Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, IBS-C Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the IBS-C Drugs sales, revenue and market share for each player covered in this report.
The major players covered in IBS-C Drugs are:
Catalent Pharmaceuticals Solutions
Ardelyx, Inc
Synergy Pharmaceuticals
Nestle
Astellas Pharmaceuticals
Abbott Laboratories
Teva Pharmaceutical Industries
Novartis Pharma Ag
Sucampo Pharmaceuticals
Synthetic Biologics, Inc
Norgine B.V
Albireo Pharma Inc
Bama-Geve, SLU
Astrazeneca Plc
Prometheus Laboratories Inc
Salix Pharmaceuticals Ltd
Ferring BV
Yuhan Corp
Actavis Nordic A/S
Ironwood Pharmaceuticals, Inc
The Menarini Group
Ono Pharmaceutical Co., Ltd
Table of Contents
1 IBS-C Drugs Market Overview
1.1 Product Overview and Scope of IBS-C Drugs
1.2 Classification of IBS-C Drugs by Type
1.2.1 Global IBS-C Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global IBS-C Drugs Revenue Market Share by Type in 2019
1.2.3 Linaclotide
1.2.4 Lubiprostone
1.2.5 Osmotic Laxatives
1.2.6 Stimulant Laxatives
1.2.7 Other
1.3 Global IBS-C Drugs Market by Application
1.3.1 Overview: Global IBS-C Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global IBS-C Drugs Market by Regions
1.4.1 Global IBS-C Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of IBS-C Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) IBS-C Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) IBS-C Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) IBS-C Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) IBS-C Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) IBS-C Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 Catalent Pharmaceuticals Solutions
2.1.1 Catalent Pharmaceuticals Solutions Details
2.1.2 Catalent Pharmaceuticals Solutions Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Catalent Pharmaceuticals Solutions SWOT Analysis
2.1.4 Catalent Pharmaceuticals Solutions Product and Services
2.1.5 Catalent Pharmaceuticals Solutions IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Ardelyx, Inc
2.2.1 Ardelyx, Inc Details
2.2.2 Ardelyx, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Ardelyx, Inc SWOT Analysis
2.2.4 Ardelyx, Inc Product and Services
2.2.5 Ardelyx, Inc IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Synergy Pharmaceuticals
2.3.1 Synergy Pharmaceuticals Details
2.3.2 Synergy Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Synergy Pharmaceuticals SWOT Analysis
2.3.4 Synergy Pharmaceuticals Product and Services
2.3.5 Synergy Pharmaceuticals IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Nestle
2.4.1 Nestle Details
2.4.2 Nestle Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Nestle SWOT Analysis
2.4.4 Nestle Product and Services
2.4.5 Nestle IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Astellas Pharmaceuticals
2.5.1 Astellas Pharmaceuticals Details
2.5.2 Astellas Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Astellas Pharmaceuticals SWOT Analysis
2.5.4 Astellas Pharmaceuticals Product and Services
2.5.5 Astellas Pharmaceuticals IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Abbott Laboratories
2.6.1 Abbott Laboratories Details
2.6.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Abbott Laboratories SWOT Analysis
2.6.4 Abbott Laboratories Product and Services
2.6.5 Abbott Laboratories IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Teva Pharmaceutical Industries
2.7.1 Teva Pharmaceutical Industries Details
2.7.2 Teva Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Teva Pharmaceutical Industries SWOT Analysis
2.7.4 Teva Pharmaceutical Industries Product and Services
2.7.5 Teva Pharmaceutical Industries IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis Pharma Ag
2.8.1 Novartis Pharma Ag Details
2.8.2 Novartis Pharma Ag Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Novartis Pharma Ag SWOT Analysis
2.8.4 Novartis Pharma Ag Product and Services
2.8.5 Novartis Pharma Ag IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Sucampo Pharmaceuticals
2.9.1 Sucampo Pharmaceuticals Details
2.9.2 Sucampo Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Sucampo Pharmaceuticals SWOT Analysis
2.9.4 Sucampo Pharmaceuticals Product and Services
2.9.5 Sucampo Pharmaceuticals IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 Synthetic Biologics, Inc
2.10.1 Synthetic Biologics, Inc Details
2.10.2 Synthetic Biologics, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Synthetic Biologics, Inc SWOT Analysis
2.10.4 Synthetic Biologics, Inc Product and Services
2.10.5 Synthetic Biologics, Inc IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 Norgine B.V
2.11.1 Norgine B.V Details
2.11.2 Norgine B.V Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Norgine B.V SWOT Analysis
2.11.4 Norgine B.V Product and Services
2.11.5 Norgine B.V IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.12 Albireo Pharma Inc
2.12.1 Albireo Pharma Inc Details
2.12.2 Albireo Pharma Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Albireo Pharma Inc SWOT Analysis
2.12.4 Albireo Pharma Inc Product and Services
2.12.5 Albireo Pharma Inc IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.13 Bama-Geve, SLU
2.13.1 Bama-Geve, SLU Details
2.13.2 Bama-Geve, SLU Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Bama-Geve, SLU SWOT Analysis
2.13.4 Bama-Geve, SLU Product and Services
2.13.5 Bama-Geve, SLU IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.14 Astrazeneca Plc
2.14.1 Astrazeneca Plc Details
2.14.2 Astrazeneca Plc Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Astrazeneca Plc SWOT Analysis
2.14.4 Astrazeneca Plc Product and Services
2.14.5 Astrazeneca Plc IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.15 Prometheus Laboratories Inc
2.15.1 Prometheus Laboratories Inc Details
2.15.2 Prometheus Laboratories Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Prometheus Laboratories Inc SWOT Analysis
2.15.4 Prometheus Laboratories Inc Product and Services
2.15.5 Prometheus Laboratories Inc IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.16 Salix Pharmaceuticals Ltd
2.16.1 Salix Pharmaceuticals Ltd Details
2.16.2 Salix Pharmaceuticals Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Salix Pharmaceuticals Ltd SWOT Analysis
2.16.4 Salix Pharmaceuticals Ltd Product and Services
2.16.5 Salix Pharmaceuticals Ltd IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.17 Ferring BV
2.17.1 Ferring BV Details
2.17.2 Ferring BV Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Ferring BV SWOT Analysis
2.17.4 Ferring BV Product and Services
2.17.5 Ferring BV IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.18 Yuhan Corp
2.18.1 Yuhan Corp Details
2.18.2 Yuhan Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Yuhan Corp SWOT Analysis
2.18.4 Yuhan Corp Product and Services
2.18.3 Yuhan Corp IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.19 Actavis Nordic A/S
2.19.1 Actavis Nordic A/S Details
2.19.2 Actavis Nordic A/S Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Actavis Nordic A/S SWOT Analysis
2.19.4 Actavis Nordic A/S Product and Services
2.19.5 Actavis Nordic A/S IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.20 Ironwood Pharmaceuticals, Inc
2.20.1 Ironwood Pharmaceuticals, Inc Details
2.20.2 Ironwood Pharmaceuticals, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Ironwood Pharmaceuticals, Inc SWOT Analysis
2.20.4 Ironwood Pharmaceuticals, Inc Product and Services
2.20.5 Ironwood Pharmaceuticals, Inc IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.21 The Menarini Group
2.21.1 The Menarini Group Details
2.21.2 The Menarini Group Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 The Menarini Group SWOT Analysis
2.21.4 The Menarini Group Product and Services
2.21.5 The Menarini Group IBS-C Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.22 Ono Pharmaceutical Co., Ltd
3 Market Competition, by Players
3.1 Global IBS-C Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 IBS-C Drugs Players Market Share
3.2.2 Top 10 IBS-C Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global IBS-C Drugs Revenue and Market Share by Regions
4.2 North America IBS-C Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe IBS-C Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific IBS-C Drugs Revenue and Growth Rate (2015-2020)
4.5 South America IBS-C Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa IBS-C Drugs Revenue and Growth Rate (2015-2020)
5 North America IBS-C Drugs Revenue by Countries
5.1 North America IBS-C Drugs Revenue by Countries (2015-2020)
5.2 USA IBS-C Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada IBS-C Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico IBS-C Drugs Revenue and Growth Rate (2015-2020)
6 Europe IBS-C Drugs Revenue by Countries
6.1 Europe IBS-C Drugs Revenue by Countries (2015-2020)
6.2 Germany IBS-C Drugs Revenue and Growth Rate (2015-2020)
6.3 UK IBS-C Drugs Revenue and Growth Rate (2015-2020)
6.4 France IBS-C Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia IBS-C Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy IBS-C Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific IBS-C Drugs Revenue by Countries
7.1 Asia-Pacific IBS-C Drugs Revenue by Countries (2015-2020)
7.2 China IBS-C Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan IBS-C Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea IBS-C Drugs Revenue and Growth Rate (2015-2020)
7.5 India IBS-C Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia IBS-C Drugs Revenue and Growth Rate (2015-2020)
8 South America IBS-C Drugs Revenue by Countries
8.1 South America IBS-C Drugs Revenue by Countries (2015-2020)
8.2 Brazil IBS-C Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina IBS-C Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue IBS-C Drugs by Countries
9.1 Middle East & Africa IBS-C Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia IBS-C Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE IBS-C Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt IBS-C Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa IBS-C Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global IBS-C Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global IBS-C Drugs Market Forecast by Type (2019-2024)
10.3 Linaclotide Revenue Growth Rate (2015-2025)
10.4 Lubiprostone Revenue Growth Rate (2015-2025)
10.5 Osmotic Laxatives Revenue Growth Rate (2015-2025)
10.6 Stimulant Laxatives Revenue Growth Rate (2015-2025)
10.7 Other Revenue Growth Rate (2015-2025)
11 Global IBS-C Drugs Market Segment by Application
11.1 Global IBS-C Drugs Revenue Market Share by Application (2015-2020)
11.2 IBS-C Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
11.5 Online Pharmacies Revenue Growth (2015-2020)
12 Global IBS-C Drugs Market Size Forecast (2021-2025)
12.1 Global IBS-C Drugs Market Size Forecast (2021-2025)
12.2 Global IBS-C Drugs Market Forecast by Regions (2021-2025)
12.3 North America IBS-C Drugs Revenue Market Forecast (2021-2025)
12.4 Europe IBS-C Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific IBS-C Drugs Revenue Market Forecast (2021-2025)
12.6 South America IBS-C Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa IBS-C Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global IBS-C Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of IBS-C Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global IBS-C Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market IBS-C Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Catalent Pharmaceuticals Solutions Corporate Information, Location and Competitors
Table 6. Catalent Pharmaceuticals Solutions IBS-C Drugs Major Business
Table 7. Catalent Pharmaceuticals Solutions IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 8. Catalent Pharmaceuticals Solutions SWOT Analysis
Table 9. Catalent Pharmaceuticals Solutions IBS-C Drugs Product and Solutions
Table 10. Catalent Pharmaceuticals Solutions IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Ardelyx, Inc Corporate Information, Location and Competitors
Table 12. Ardelyx, Inc IBS-C Drugs Major Business
Table 13. Ardelyx, Inc IBS-C Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Ardelyx, Inc SWOT Analysis
Table 15. Ardelyx, Inc IBS-C Drugs Product and Solutions
Table 16. Ardelyx, Inc IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Synergy Pharmaceuticals Corporate Information, Location and Competitors
Table 18. Synergy Pharmaceuticals IBS-C Drugs Major Business
Table 19. Synergy Pharmaceuticals IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Synergy Pharmaceuticals SWOT Analysis
Table 21. Synergy Pharmaceuticals IBS-C Drugs Product and Solutions
Table 22. Synergy Pharmaceuticals IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Nestle Corporate Information, Location and Competitors
Table 24. Nestle IBS-C Drugs Major Business
Table 25. Nestle IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Nestle SWOT Analysis
Table 27. Nestle IBS-C Drugs Product and Solutions
Table 28. Nestle IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Astellas Pharmaceuticals Corporate Information, Location and Competitors
Table 30. Astellas Pharmaceuticals IBS-C Drugs Major Business
Table 31. Astellas Pharmaceuticals IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Astellas Pharmaceuticals SWOT Analysis
Table 33. Astellas Pharmaceuticals IBS-C Drugs Product and Solutions
Table 34. Astellas Pharmaceuticals IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Abbott Laboratories Corporate Information, Location and Competitors
Table 36. Abbott Laboratories IBS-C Drugs Major Business
Table 37. Abbott Laboratories IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Abbott Laboratories SWOT Analysis
Table 39. Abbott Laboratories IBS-C Drugs Product and Solutions
Table 40. Abbott Laboratories IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Teva Pharmaceutical Industries Corporate Information, Location and Competitors
Table 42. Teva Pharmaceutical Industries IBS-C Drugs Major Business
Table 43. Teva Pharmaceutical Industries IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Teva Pharmaceutical Industries SWOT Analysis
Table 45. Teva Pharmaceutical Industries IBS-C Drugs Product and Solutions
Table 46. Teva Pharmaceutical Industries IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Novartis Pharma Ag Corporate Information, Location and Competitors
Table 48. Novartis Pharma Ag IBS-C Drugs Major Business
Table 49. Novartis Pharma Ag IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Novartis Pharma Ag SWOT Analysis
Table 51. Novartis Pharma Ag IBS-C Drugs Product and Solutions
Table 52. Novartis Pharma Ag IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Sucampo Pharmaceuticals Corporate Information, Location and Competitors
Table 54. Sucampo Pharmaceuticals IBS-C Drugs Major Business
Table 55. Sucampo Pharmaceuticals IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Sucampo Pharmaceuticals SWOT Analysis
Table 57. Sucampo Pharmaceuticals IBS-C Drugs Product and Solutions
Table 58. Sucampo Pharmaceuticals IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Synthetic Biologics, Inc Corporate Information, Location and Competitors
Table 60. Synthetic Biologics, Inc IBS-C Drugs Major Business
Table 61. Synthetic Biologics, Inc IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 62. Synthetic Biologics, Inc SWOT Analysis
Table 63. Synthetic Biologics, Inc IBS-C Drugs Product and Solutions
Table 64. Synthetic Biologics, Inc IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Norgine B.V Corporate Information, Location and Competitors
Table 66. Norgine B.V IBS-C Drugs Major Business
Table 67. Norgine B.V IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 68. Norgine B.V SWOT Analysis
Table 69. Norgine B.V IBS-C Drugs Product and Solutions
Table 70. Norgine B.V IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Albireo Pharma Inc Corporate Information, Location and Competitors
Table 72. Albireo Pharma Inc IBS-C Drugs Major Business
Table 73. Albireo Pharma Inc IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 74. Albireo Pharma Inc SWOT Analysis
Table 75. Albireo Pharma Inc IBS-C Drugs Product and Solutions
Table 76. Albireo Pharma Inc IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Bama-Geve, SLU Corporate Information, Location and Competitors
Table 78. Bama-Geve, SLU IBS-C Drugs Major Business
Table 79. Bama-Geve, SLU IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 80. Bama-Geve, SLU SWOT Analysis
Table 81. Bama-Geve, SLU IBS-C Drugs Product and Solutions
Table 82. Bama-Geve, SLU IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Astrazeneca Plc Corporate Information, Location and Competitors
Table 84. Astrazeneca Plc IBS-C Drugs Major Business
Table 85. Astrazeneca Plc IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 86. Astrazeneca Plc SWOT Analysis
Table 87. Astrazeneca Plc IBS-C Drugs Product and Solutions
Table 88. Astrazeneca Plc IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Prometheus Laboratories Inc Corporate Information, Location and Competitors
Table 90. Prometheus Laboratories Inc IBS-C Drugs Major Business
Table 91. Prometheus Laboratories Inc IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 92. Prometheus Laboratories Inc SWOT Analysis
Table 93. Prometheus Laboratories Inc IBS-C Drugs Product and Solutions
Table 94. Prometheus Laboratories Inc IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Salix Pharmaceuticals Ltd Corporate Information, Location and Competitors
Table 96. Salix Pharmaceuticals Ltd IBS-C Drugs Major Business
Table 97. Salix Pharmaceuticals Ltd IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 98. Salix Pharmaceuticals Ltd SWOT Analysis
Table 99. Salix Pharmaceuticals Ltd IBS-C Drugs Product and Solutions
Table 100. Salix Pharmaceuticals Ltd IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Ferring BV Corporate Information, Location and Competitors
Table 102. Ferring BV IBS-C Drugs Major Business
Table 103. Ferring BV IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 104. Ferring BV SWOT Analysis
Table 105. Ferring BV IBS-C Drugs Product and Solutions
Table 106. Ferring BV IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Yuhan Corp IBS-C Drugs Type and Application
Table 108. Yuhan Corp IBS-C Drugs Major Business
Table 109. Yuhan Corp IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 110. Yuhan Corp SWOT Analysis
Table 111. Yuhan Corp IBS-C Drugs Product and Solutions
Table 112. Yuhan Corp IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Actavis Nordic A/S Corporate Information, Location and Competitors
Table 114. Actavis Nordic A/S IBS-C Drugs Major Business
Table 115. Actavis Nordic A/S IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 116. Actavis Nordic A/S SWOT Analysis
Table 117. Actavis Nordic A/S IBS-C Drugs Product and Solutions
Table 118. Actavis Nordic A/S IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. Ironwood Pharmaceuticals, Inc Corporate Information, Location and Competitors
Table 120. Ironwood Pharmaceuticals, Inc IBS-C Drugs Major Business
Table 121. Ironwood Pharmaceuticals, Inc IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 122. Ironwood Pharmaceuticals, Inc SWOT Analysis
Table 123. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product and Solutions
Table 124. Ironwood Pharmaceuticals, Inc IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 125. The Menarini Group Corporate Information, Location and Competitors
Table 126. The Menarini Group IBS-C Drugs Major Business
Table 127. The Menarini Group IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 128. The Menarini Group SWOT Analysis
Table 129. The Menarini Group IBS-C Drugs Product and Solutions
Table 130. The Menarini Group IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 131. Ono Pharmaceutical Co., Ltd Corporate Information, Location and Competitors
Table 132. Ono Pharmaceutical Co., Ltd IBS-C Drugs Major Business
Table 133. Ono Pharmaceutical Co., Ltd IBS-C Drugs Total Revenue (USD Million) (2017-2018)
Table 134. Ono Pharmaceutical Co., Ltd SWOT Analysis
Table 135. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product and Solutions
Table 136. Ono Pharmaceutical Co., Ltd IBS-C Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 137. Global IBS-C Drugs Revenue (Million USD) by Players (2015-2020)
Table 138. Global IBS-C Drugs Revenue Share by Players (2015-2020)
Table 139. Global IBS-C Drugs Revenue (Million USD) by Regions (2015-2020)
Table 140. Global IBS-C Drugs Revenue Market Share by Regions (2015-2020)
Table 141. North America IBS-C Drugs Revenue by Countries (2015-2020)
Table 142. North America IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Table 143. Europe IBS-C Drugs Revenue (Million USD) by Countries (2015-2020)
Table 144. Asia-Pacific IBS-C Drugs Revenue (Million USD) by Countries (2015-2020)
Table 145. South America IBS-C Drugs Revenue by Countries (2015-2020)
Table 146. South America IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Table 147. Middle East and Africa IBS-C Drugs Revenue (Million USD) by Countries (2015-2020)
Table 148. Middle East and Africa IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Table 149. Global IBS-C Drugs Revenue (Million USD) by Type (2015-2020)
Table 150. Global IBS-C Drugs Revenue Share by Type (2015-2020)
Table 151. Global IBS-C Drugs Revenue Forecast by Type (2021-2025)
Table 152. Global IBS-C Drugs Revenue by Application (2015-2020)
Table 153. Global IBS-C Drugs Revenue Share by Application (2015-2020)
Table 154. Global IBS-C Drugs Revenue Forecast by Application (2021-2025)
Table 155. Global IBS-C Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. IBS-C Drugs Picture
Figure 2. Global IBS-C Drugs Revenue Market Share by Type in 2019
Figure 3. Linaclotide Picture
Figure 4. Lubiprostone Picture
Figure 5. Osmotic Laxatives Picture
Figure 6. Stimulant Laxatives Picture
Figure 7. Other Picture
Figure 8. IBS-C Drugs Revenue Market Share by Application in 2019
Figure 9. Hospital Pharmacies Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Online Pharmacies Picture
Figure 12. Global IBS-C Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America IBS-C Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe IBS-C Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific IBS-C Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America IBS-C Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa IBS-C Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global IBS-C Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global IBS-C Drugs Revenue Share by Players in 2019
Figure 20. Global Top 5 Players IBS-C Drugs Revenue Market Share in 2019
Figure 21. Global Top 10 Players IBS-C Drugs Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global IBS-C Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global IBS-C Drugs Revenue Market Share by Regions (2015-2020)
Figure 25. Global IBS-C Drugs Revenue Market Share by Regions in 2018
Figure 26. North America IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Europe IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 29. South America IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 31. North America IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Figure 32. North America IBS-C Drugs Revenue Market Share by Countries in 2019
Figure 33. USA IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 34. Canada IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 35. Mexico IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Europe IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Figure 37. Europe IBS-C Drugs Revenue Market Share by Countries in 2019
Figure 38. Germany IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 39. UK IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 40. France IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 41. Russia IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 42. Italy IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific IBS-C Drugs Revenue Market Share by Countries in 2019
Figure 45. China IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Japan IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 47. Korea IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 48. India IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 50. South America IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Figure 51. South America IBS-C Drugs Revenue Market Share by Countries in 2019
Figure 52. Brazil IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 53. Argentina IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa IBS-C Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa IBS-C Drugs Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 57. UAE IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 58. Egypt IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 59. South Africa IBS-C Drugs Revenue and Growth Rate (2015-2020)
Figure 60. Global IBS-C Drugs Revenue Share by Type (2015-2020)
Figure 61. Global IBS-C Drugs Revenue Share by Type in 2019
Figure 62. Global IBS-C Drugs Market Share Forecast by Type (2021-2025)
Figure 63. Global Linaclotide Revenue Growth Rate (2015-2020)
Figure 64. Global Lubiprostone Revenue Growth Rate (2015-2020)
Figure 65. Global Osmotic Laxatives Revenue Growth Rate (2015-2020)
Figure 66. Global Stimulant Laxatives Revenue Growth Rate (2015-2020)
Figure 67. Global Other Revenue Growth Rate (2015-2020)
Figure 68. Global IBS-C Drugs Revenue Share by Application (2015-2020)
Figure 69. Global IBS-C Drugs Revenue Share by Application in 2019
Figure 70. Global IBS-C Drugs Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 72. Global Retail Pharmacies Revenue Growth Rate (2015-2020)
Figure 73. Global Online Pharmacies Revenue Growth Rate (2015-2020)
Figure 74. Global IBS-C Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global IBS-C Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global IBS-C Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America IBS-C Drugs Revenue Market Forecast (2021-2025)
Figure 78. Europe IBS-C Drugs Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific IBS-C Drugs Revenue Market Forecast (2021-2025)
Figure 80. South America IBS-C Drugs Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa IBS-C Drugs Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
イロプロスト治療薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Iloprost Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…
- 自己免疫治療薬の世界市場（～2026年） Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by c…
- チロシンヒドロキシラーゼ欠損症治療薬の世界市場（～2026年） The Tyrosine Hydroxylase Deficiency is also known as recessive dopa-responsive dystonia and is a rare genetic disorder. In the Tyrosine Hydroxylase Deficiency, there is lack of enzymes which are involved in converting amino acid tyrosine to L-dopa. A wide range of symptoms can be associated with the…